{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:36:55Z","timestamp":1792089415654,"version":"4.4.0"},"reference-count":132,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004593","name":"Universidad Aut\u00f3noma de Madrid","doi-asserted-by":"publisher","award":["UAM\/133"],"award-info":[{"award-number":["UAM\/133"]}],"id":[{"id":"10.13039\/501100004593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0027\/0008"],"award-info":[{"award-number":["RD16\/0027\/0008"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017607","name":"Universidad Autonoma de Madrid Centro de Biologia Molecular Severo Ochoa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["RTI2018-094484-B-I00"],"award-info":[{"award-number":["RTI2018-094484-B-I00"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["RYC-2016-19463"],"award-info":[{"award-number":["RYC-2016-19463"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Parasitology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.pt.2021.11.004","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T08:23:05Z","timestamp":1639038185000},"page":"316-334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Live attenuated vaccines, a favorable strategy to provide long-term immunity against protozoan diseases"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0485-6127","authenticated-orcid":false,"given":"Jose C.","family":"Solana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0087-4659","authenticated-orcid":false,"given":"Javier","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1607-1749","authenticated-orcid":false,"given":"Salvador","family":"Iborra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-841X","authenticated-orcid":false,"given":"Manuel","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7550-0198","authenticated-orcid":false,"given":"Jose M.","family":"Requena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pt.2021.11.004_bb0005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/ni.2853","article-title":"Vaccines against tropical parasitic diseases: a persisting answer to a persisting problem","volume":"15","author":"Sacks","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0010","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.pt.2011.01.002","article-title":"Harnessing immune responses against Plasmodium for rational vaccine design","volume":"27","author":"Douradinha","year":"2011","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2021.11.004_bb0015","first-page":"16","article-title":"The case for the development of a Chagas disease vaccine: Why? How? When?","volume":"6","author":"Dumonteil","year":"2021","journal-title":"Trop. Med. Infect. Dis."},{"key":"10.1016\/j.pt.2021.11.004_bb0020","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(19)30937-7","article-title":"RTS,S malaria vaccine pilots in three African countries","volume":"393","author":"Adepoju","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2021.11.004_bb0025","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/tmi.13382","article-title":"Commercially approved vaccines for canine leishmaniosis: a review of available data on their safety and efficacy","volume":"25","author":"Velez","year":"2020","journal-title":"Tropical Med. Int. Health"},{"key":"10.1016\/j.pt.2021.11.004_bb0030","first-page":"480","article-title":"Deception and manipulation: the arms of leishmania, a successful parasite","volume":"5","author":"Cecilio","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165707","article-title":"Signaling pathways that regulate Trypanosoma cruzi infection and immune response","volume":"1866","author":"Cerban","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"key":"10.1016\/j.pt.2021.11.004_bb0040","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fimmu.2020.00204","article-title":"The delay in the licensing of protozoal vaccines: a comparative history","volume":"11","author":"Palatnik-de-Sousa","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0045","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00062-17","article-title":"Chemical attenuation in the development of a whole-organism malaria vaccine","volume":"85","author":"Raja","year":"2017","journal-title":"Infect. Immun."},{"key":"10.1016\/j.pt.2021.11.004_bb0050","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12936-020-3141-z","article-title":"Plasmodium falciparum pre-erythrocytic stage vaccine development","volume":"19","author":"Molina-Franky","year":"2020","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2021.11.004_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2019.105173","article-title":"An overview of leishmanization experience: A successful control measure and a tool to evaluate candidate vaccines","volume":"200","author":"Mohebali","year":"2019","journal-title":"Acta Trop."},{"key":"10.1016\/j.pt.2021.11.004_bb0060","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4269\/ajtmh.1993.49.143","article-title":"Field trial of vaccination against American trypanosomiasis (Chagas' disease) in dogs","volume":"49","author":"Basombrio","year":"1993","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2021.11.004_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006960","article-title":"Protection by and maintenance of CD4 effector memory and effector T cell subsets in persistent malaria infection","volume":"14","author":"Opata","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2021.11.004_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1015","article-title":"Induction of immunity following vaccination with a chemically attenuated malaria vaccine correlates with persistent antigenic stimulation","volume":"7","author":"Reiman","year":"2018","journal-title":"Clin. Translat. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0075","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1645\/0022-3395(2002)088[1107:RBLTRT]2.0.CO;2","article-title":"Relationship between long-term resistance to Trypanosoma cruzi and latent infection, examined by antibody production and polymerase chain reaction in mice","volume":"88","author":"Basombrio","year":"2002","journal-title":"J. Parasitol."},{"key":"10.1016\/j.pt.2021.11.004_bb0080","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1073\/pnas.92.9.4066","article-title":"Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites","volume":"92","author":"Scheller","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2021.11.004_bb0085","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12026-008-8016-2","article-title":"Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies","volume":"41","author":"Okwor","year":"2008","journal-title":"Immunol. Res."},{"key":"10.1016\/j.pt.2021.11.004_bb0090","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.0105-2896.2004.00181.x","article-title":"Does malaria suffer from lack of memory?","volume":"201","author":"Struik","year":"2004","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.pt.2021.11.004_bb0095","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pt.2016.09.012","article-title":"Time for genome editing: next-generation attenuated malaria parasites","volume":"33","author":"Singer","year":"2017","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2021.11.004_bb0100","doi-asserted-by":"crossref","DOI":"10.1111\/pim.12732","article-title":"Genetically modified live attenuated vaccine: A potential strategy to combat visceral leishmaniasis","volume":"42","author":"Pandey","year":"2020","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0105","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4161\/bioe.20680","article-title":"Genetically attenuated Trypanosoma cruzi parasites as a potential vaccination tool","volume":"3","author":"Perez Brandan","year":"2012","journal-title":"Bioengineered"},{"key":"10.1016\/j.pt.2021.11.004_bb0110","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41590-018-0228-6","article-title":"Malaria prevention: from immunological concepts to effective vaccines and protective antibodies","volume":"19","author":"Cockburn","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0115","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/216160a0","article-title":"Protective Immunity produced by the Injection of X-irradiated sporozoites of Plasmodium berghei","volume":"216","author":"Nussenzweig","year":"1967","journal-title":"Nature"},{"key":"10.1016\/j.pt.2021.11.004_bb0120","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.4049\/jimmunol.181.12.8552","article-title":"Vaccination with live Plasmodium yoelii blood stage parasites under chloroquine cover induces cross-stage immunity against malaria liver stage","volume":"181","author":"Belnoue","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0125","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4161\/hv.6.1.10396","article-title":"Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria","volume":"6","author":"Hoffman","year":"2010","journal-title":"Hum. Vaccin."},{"key":"10.1016\/j.pt.2021.11.004_bb0130","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1126\/science.1241800","article-title":"Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine","volume":"341","author":"Seder","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.pt.2021.11.004_bb0135","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1073\/pnas.1615324114","article-title":"Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection","volume":"114","author":"Lyke","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2021.11.004_bb0140","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","article-title":"Safety and efficacy of PfSPZ vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial","volume":"17","author":"Sissoko","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2021.11.004_bb0145","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.4269\/ajtmh.18-0835","article-title":"Safety and differential antibody and T-cell responses to the Plasmodium falciparum sporozoite malaria vaccine, PfSPZ vaccine, by age in Tanzanian adults, adolescents, children, and infants","volume":"100","author":"Jongo","year":"2019","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2021.11.004_bb0150","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4269\/ajtmh.17-0449","article-title":"Advancing global health through development and clinical trials partnerships: a randomized, placebo-controlled, double-blind assessment of safety, tolerability, and immunogenicity of PfSPZ vaccine for malaria in healthy Equatoguinean men","volume":"98","author":"Olotu","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2021.11.004_bb0155","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4269\/ajtmh.20-0435","article-title":"Immunogenicity and protective efficacy of radiation-attenuated and chemo-attenuated PfSPZ vaccines in Equatoguinean adults","volume":"104","author":"Jongo","year":"2021","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2021.11.004_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009594","article-title":"PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection","volume":"17","author":"Murphy","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2021.11.004_bb0165","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00587-18","article-title":"Controlled infection immunization using delayed death drug treatment elicits protective immune responses to blood-stage malaria parasites","volume":"87","author":"Low","year":"2019","journal-title":"Infect. Immun."},{"key":"10.1016\/j.pt.2021.11.004_bb0170","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12916-018-1173-9","article-title":"Vaccination with chemically attenuated Plasmodium falciparum asexual blood-stage parasites induces parasite-specific cellular immune responses in malaria-na\u00efve volunteers: a pilot study","volume":"16","author":"Stanisic","year":"2018","journal-title":"BMC Med."},{"key":"10.1016\/j.pt.2021.11.004_bb0175","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-021-03684-z","article-title":"Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity","volume":"595","author":"Mwakingwe-Omari","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.pt.2021.11.004_bb0180","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/imr.12819","article-title":"Whole parasite vaccines for the asexual blood stages of Plasmodium","volume":"293","author":"Good","year":"2020","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.pt.2021.11.004_bb0185","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1365-2958.2008.06271.x","article-title":"Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection","volume":"69","author":"Aly","year":"2008","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.pt.2021.11.004_bb0190","doi-asserted-by":"crossref","first-page":"12194","DOI":"10.1073\/pnas.0500925102","article-title":"Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells","volume":"102","author":"van Dijk","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2021.11.004_bb0195","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1086\/519742","article-title":"Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells","volume":"196","author":"Tarun","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2021.11.004_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003549","article-title":"Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes","volume":"3","author":"van Schaijk","year":"2008","journal-title":"PLOS ONE"},{"key":"10.1016\/j.pt.2021.11.004_bb0205","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1096\/fj.13-241570","article-title":"Two Plasmodium 6-Cys family-related proteins have distinct and critical roles in liver-stage development","volume":"28","author":"Annoura","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.pt.2021.11.004_bb0210","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1111\/j.1365-2958.2011.07787.x","article-title":"Inactivation of a Plasmodium apicoplast protein attenuates formation of liver merozoites","volume":"81","author":"Haussig","year":"2011","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.pt.2021.11.004_bb0215","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4269\/ajtmh.16-0226","article-title":"Protective efficacy induced by genetically attenuated mid-to-late liver-stage arresting Plasmodium berghei Deltamrp2 parasites","volume":"95","author":"van der Velden","year":"2016","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2021.11.004_bb0220","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/j.1365-2958.2009.07034.x","article-title":"Plasmodium pyruvate dehydrogenase activity is only essential for the parasite's progression from liver infection to blood infection","volume":"75","author":"Pei","year":"2010","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.pt.2021.11.004_bb0225","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.chom.2011.05.008","article-title":"Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites","volume":"9","author":"Butler","year":"2011","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.pt.2021.11.004_bb0230","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1086\/519743","article-title":"Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex Class I-dependent interferon-gamma-producing CD8+ T cells","volume":"196","author":"Jobe","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2021.11.004_bb0235","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03582","article-title":"A genetically attenuated malaria vaccine candidate based on P. falciparum b9\/slarp gene-deficient sporozoites","volume":"3","author":"van Schaijk","year":"2014","journal-title":"eLife"},{"key":"10.1016\/j.pt.2021.11.004_bb0240","doi-asserted-by":"crossref","first-page":"13004","DOI":"10.1073\/pnas.0906387106","article-title":"Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design","volume":"106","author":"VanBuskirk","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2021.11.004_bb0245","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1016\/j.vaccine.2013.08.007","article-title":"First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers","volume":"31","author":"Spring","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.pt.2021.11.004_bb0250","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/mt.2014.85","article-title":"A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion","volume":"22","author":"Mikolajczak","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.pt.2021.11.004_bb0255","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad9099","article-title":"Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects","volume":"9","author":"Kublin","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2021.11.004_bb0260","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135589","article-title":"A replication-competent late liver stage-attenuated human malaria parasite","volume":"5","author":"Goswami","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.pt.2021.11.004_bb0265","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/nm.1867","article-title":"Attenuated Plasmodium yoelii lacking purine nucleoside phosphorylase confer protective immunity","volume":"14","author":"Ting","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.pt.2021.11.004_bb0270","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1462-5822.2010.01441.x","article-title":"Subpatent infection with nucleoside transporter 1-deficient Plasmodium blood stage parasites confers sterile protection against lethal malaria in mice","volume":"12","author":"Aly","year":"2010","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.pt.2021.11.004_bb0275","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/srep00039","article-title":"Disruption of plasmepsin-4 and merozoites surface protein-7 genes in Plasmodium berghei induces combined virulence-attenuated phenotype","volume":"1","author":"Spaccapelo","year":"2011","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pt.2021.11.004_bb0280","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1084\/jem.20151976","article-title":"Protection against malaria in mice is induced by blood stage-arresting histamine-releasing factor (HRF)-deficient parasites","volume":"213","author":"Demarta-Gatsi","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.pt.2021.11.004_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232183","article-title":"A genetically hmgb2 attenuated blood stage P. berghei induces crossed-long live protection","volume":"15","author":"Briquet","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.pt.2021.11.004_bb0290","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.pt.2019.08.006","article-title":"Understanding CD8(+) T cell immunity to Trypanosoma cruzi and how to improve it","volume":"35","author":"Acosta Rodriguez","year":"2019","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2021.11.004_bb0295","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-3024.2009.01108.x","article-title":"The role of parasite persistence in pathogenesis of Chagas heart disease","volume":"31","author":"Gutierrez","year":"2009","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0300","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1128\/iai.36.1.351-356.1982","article-title":"Trypanosoma cruzi culture used as vaccine to prevent chronic Chagas' disease in mice","volume":"36","author":"Basombr\u00edo","year":"1982","journal-title":"Infect. Immun."},{"key":"10.1016\/j.pt.2021.11.004_bb0305","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.exppara.2007.05.005","article-title":"Trypanosoma cruzi: attenuation of virulence and protective immunogenicity after monoallelic disruption of the cub gene","volume":"117","author":"Barrio","year":"2007","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.pt.2021.11.004_bb0310","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1128\/IAI.00400-07","article-title":"Impairment of infectivity and immunoprotective effect of a LYT1 null mutant of Trypanosoma cruzi","volume":"76","author":"Zago","year":"2008","journal-title":"Infect. Immun."},{"key":"10.1016\/j.pt.2021.11.004_bb0315","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1645\/0022-3395(2002)088[0489:TDOTGG]2.0.CO;2","article-title":"Targeted deletion of the gp72 gene decreases the infectivity of Trypanosoma cruzi for mice and insect vectors","volume":"88","author":"Basombrio","year":"2002","journal-title":"J. Parasitol."},{"key":"10.1016\/j.pt.2021.11.004_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001418","article-title":"Knockout of the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able to confer protection against a virulent challenge","volume":"5","author":"Perez Brandan","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2021.11.004_bb0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002696","article-title":"A monoallelic deletion of the TcCRT gene increases the attenuation of a cultured Trypanosoma cruzi strain, protecting against an in vivo virulent challenge","volume":"8","author":"Sanchez-Valdez","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2021.11.004_bb0330","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1128\/IAI.01080-10","article-title":"Oral exposure to Trypanosoma cruzi elicits a systemic CD8(+) T cell response and protection against heterotopic challenge","volume":"79","author":"Collins","year":"2011","journal-title":"Infect. Immun."},{"key":"10.1016\/j.pt.2021.11.004_bb0335","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.pt.2019.04.002","article-title":"CD4+ T cell-mediated immunity against the phagosomal pathogen Leishmania: implications for vaccination","volume":"35","author":"Hohman","year":"2019","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2021.11.004_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002757","article-title":"Gentamicin-attenuated Leishmania infantum vaccine: protection of dogs against canine visceral leishmaniosis in endemic area of southeast of Iran","volume":"8","author":"Daneshvar","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2021.11.004_bb0345","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.4049\/jimmunol.0900276","article-title":"Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis","volume":"183","author":"Selvapandiyan","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0350","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.vaccine.2014.11.039","article-title":"Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum","volume":"33","author":"Fiuza","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.pt.2021.11.004_bb0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004322","article-title":"Intradermal immunization of Leishmania donovani centrin knock-out parasites in combination with salivary protein LJM19 from sand fly vector induces a durable protective immune response in hamsters","volume":"10","author":"Fiuza","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2021.11.004_bb0360","doi-asserted-by":"crossref","first-page":"33059","DOI":"10.1038\/srep33059","article-title":"Gene deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs","volume":"6","author":"Avishek","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pt.2021.11.004_bb0365","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1756-3305-4-150","article-title":"Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation","volume":"4","author":"Carrion","year":"2011","journal-title":"Parasit. Vectors"},{"key":"10.1016\/j.pt.2021.11.004_bb0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005644","article-title":"Vaccination with a Leishmania infantum HSP70-II null mutant confers long-term protective immunity against Leishmania major infection in two mice models","volume":"11","author":"Solana","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2021.11.004_bb0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004538","article-title":"Chronic parasitic infection maintains high frequencies of short-lived Ly6C+CD4+ effector T cells that are required for protection against re-infection","volume":"10","author":"Peters","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2021.11.004_bb0380","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.4049\/jimmunol.1201676","article-title":"Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL\/6 mice","volume":"189","author":"Peters","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0385","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.4049\/jimmunol.172.6.3793","article-title":"Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response","volume":"172","author":"Uzonna","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0390","doi-asserted-by":"crossref","first-page":"10267","DOI":"10.1073\/pnas.92.22.10267","article-title":"Development of a safe live Leishmania vaccine line by gene replacement","volume":"92","author":"Titus","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2021.11.004_bb0395","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4269\/ajtmh.2004.71.297","article-title":"Cross-immunity experiments between different species or strains of Leishmania in rhesus macaques (Macaca mulatta)","volume":"71","author":"Porrozzi","year":"2004","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2021.11.004_bb0400","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.4049\/jimmunol.1500752","article-title":"Cutaneous Infection with Leishmania major mediates heterologous protection against visceral infection with Leishmania infantum","volume":"195","author":"Romano","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0405","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.vaccine.2012.11.065","article-title":"Leishmanization revisited: immunization with a naturally attenuated cutaneous Leishmania donovani isolate from Sri Lanka protects against visceral leishmaniasis","volume":"31","author":"McCall","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.pt.2021.11.004_bb0410","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.4049\/jimmunol.166.3.1921","article-title":"Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms","volume":"166","author":"Streit","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0415","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.4049\/jimmunol.1303145","article-title":"Characterization of cross-protection by genetically modified live-attenuated Leishmania donovani parasites against Leishmania mexicana","volume":"193","author":"Dey","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0420","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.4049\/jimmunol.1202801","article-title":"Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB\/c mice","volume":"190","author":"Dey","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0425","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1016\/j.vaccine.2019.04.068","article-title":"Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: Protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB\/c mice","volume":"37","author":"Elikaee","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.pt.2021.11.004_bb0430","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/vaccines8010141","article-title":"Subcutaneous immunization of Leishmania HSP70-II null mutant line reduces the severity of the experimental visceral leishmaniasis in BALB\/c mice","volume":"8","author":"Solana","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.pt.2021.11.004_bb0435","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3390\/microorganisms9020363","article-title":"Inoculation of the Leishmania infantum HSP70-II null mutant induces long-term protection against L. amazonensis infection in BALB\/c mice","volume":"9","author":"Soto","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.pt.2021.11.004_bb0440","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1038\/s41467-020-17154-z","article-title":"A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2021.11.004_bb0445","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/s42003-021-02446-x","article-title":"Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis","volume":"4","author":"Karmakar","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.pt.2021.11.004_bb0450","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1016\/j.vaccine.2005.05.045","article-title":"Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of Leishmania mexicana in non-murine models","volume":"24","author":"Saravia","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.pt.2021.11.004_bb0455","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.4049\/jimmunol.179.5.3161","article-title":"SIR2-deficient Leishmania infantum induces a defined IFN-gamma\/IL-10 pattern that correlates with protection","volume":"179","author":"Silvestre","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0460","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002785","article-title":"A dual drug sensitive L. major induces protection without lesion in C57BL\/6 mice","volume":"8","author":"Davoudi","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2021.11.004_bb0465","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fimmu.2014.00241","article-title":"Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis \u2013 discovery and implications","volume":"5","author":"Gannavaram","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0470","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006250","article-title":"Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled\/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease","volume":"12","author":"Lenk","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2021.11.004_bb0475","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00281-020-00796-y","article-title":"Implications of asymptomatic infection for the natural history of selected parasitic tropical diseases","volume":"42","author":"Alvar","year":"2020","journal-title":"Sem. Immunopathol."},{"key":"10.1016\/j.pt.2021.11.004_bb0480","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.202.Supp.196.29","article-title":"Immunization with Leishmania major centrin knock-out (LmCen\u2212\/\u2212) parasites induces skin resident memory T cells that plays a role in protection against wild type infection (LmWT)","volume":"202","author":"Ismail","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0485","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3389\/fimmu.2019.01227","article-title":"Vaccination with sporozoites: models and correlates of protection","volume":"10","author":"Goh","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2019.105168","article-title":"Immunity and vaccine development efforts against Trypanosoma cruzi","volume":"200","author":"Rios","year":"2019","journal-title":"Acta Trop."},{"key":"10.1016\/j.pt.2021.11.004_bb0495","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4103\/ijpvm.IJPVM_116_18","article-title":"Leishmania vaccines entered in clinical trials: a review of literature","volume":"10","author":"Moafi","year":"2019","journal-title":"Int. J. Prev. Med."},{"key":"10.1016\/j.pt.2021.11.004_bb0500","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41467-020-20569-3","article-title":"Characterization of a new Leishmania major strain for use in a controlled human infection model","volume":"12","author":"Ashwin","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2021.11.004_bb0505","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.pt.2018.11.010","article-title":"Plasmodium falciparum","volume":"35","author":"Maier","year":"2019","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2021.11.004_bb0510","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.pt.2019.10.002","article-title":"Trypanosoma cruzi","volume":"36","author":"Moretti","year":"2020","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2021.11.004_bb0515","series-title":"Weekly Epidemiological Record","first-page":"557","article-title":"Global leishmaniasis update, 2006\u20132015: a turning point in leishmaniasis surveillance","author":"WHO","year":"2017"},{"key":"10.1016\/j.pt.2021.11.004_bb0520","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cellimm.2016.07.010","article-title":"Memory T cells in cutaneous leishmaniasis","volume":"309","author":"Glennie","year":"2016","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0525","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006349","article-title":"Skin-resident CD4+ T cells protect against Leishmania major by recruiting and activating inflammatory monocytes","volume":"13","author":"Glennie","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2021.11.004_bb0530","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.immuni.2016.08.011","article-title":"Liver-resident memory CD8(+) T cells form a front-line defense against malaria liver-stage infection","volume":"45","author":"Fernandez-Ruiz","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.pt.2021.11.004_bb0535","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nm.4110","article-title":"Protection against malaria at 1 year and immune correlates following PfSPZ vaccination","volume":"22","author":"Ishizuka","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.pt.2021.11.004_bb0540","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/cid\/ciz925","article-title":"Safety, tolerability, and immunogenicity of PfSPZ vaccine administered by direct venous inoculation to infants and young children: findings from an age de-escalation, dose-escalation double-blinded randomized, controlled study in western Kenya","volume":"71","author":"Steinhardt","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2021.11.004_bb0545","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4269\/ajtmh.15-0621","article-title":"Safety, immunogenicity, and protective efficacy of intradermal immunization with aseptic, purified, cryopreserved Plasmodium falciparum sporozoites in volunteers under chloroquine prophylaxis: a randomized controlled trial","volume":"94","author":"Bastiaens","year":"2016","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2021.11.004_bb0550","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature21060","article-title":"Sterile protection against human malaria by chemoattenuated PfSPZ vaccine","volume":"542","author":"Mordmuller","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.pt.2021.11.004_bb0555","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1016\/j.vaccine.2008.07.017","article-title":"Chemically attenuated Plasmodium sporozoites induce specific immune responses, sterile immunity and cross-protection against heterologous challenge","volume":"26","author":"Purcell","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.pt.2021.11.004_bb0560","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1172\/JCI66634","article-title":"Cross-species malaria immunity induced by chemically attenuated parasites","volume":"123","author":"Good","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.pt.2021.11.004_bb0565","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1128\/IAI.00157-16","article-title":"Chemically attenuated blood-stage Plasmodium yoelii parasites induce long-lived and strain-transcending protection","volume":"84","author":"Raja","year":"2016","journal-title":"Infect. Immun."},{"key":"10.1016\/j.pt.2021.11.004_bb0570","doi-asserted-by":"crossref","first-page":"26824","DOI":"10.1038\/srep26824","article-title":"Protective efficacy and safety of liver stage attenuated malaria parasites","volume":"6","author":"Kumar","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pt.2021.11.004_bb0575","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1073\/pnas.0408442102","article-title":"Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface","volume":"102","author":"Mueller","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2021.11.004_bb0580","doi-asserted-by":"crossref","first-page":"5870","DOI":"10.4049\/jimmunol.0900302","article-title":"Genetically attenuated parasite vaccines induce contact-dependent CD8+ T cell killing of Plasmodium yoelii liver stage-infected hepatocytes","volume":"183","author":"Trimnell","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0585","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1128\/IAI.00225-07","article-title":"Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection","volume":"75","author":"Labaied","year":"2007","journal-title":"Infect. Immun."},{"key":"10.1016\/j.pt.2021.11.004_bb0590","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1016\/j.vaccine.2012.02.010","article-title":"Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates","volume":"30","author":"Annoura","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.pt.2021.11.004_bb0595","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00088-18","article-title":"A Plasmodium parasite with complete late liver stage arrest protects against preerythrocytic and erythrocytic stage infection in mice","volume":"86","author":"Vaughan","year":"2018","journal-title":"Infect. Immun."},{"key":"10.1016\/j.pt.2021.11.004_bb0600","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/cmi.12137","article-title":"A key role for lipoic acid synthesis during Plasmodium liver stage development","volume":"15","author":"Falkard","year":"2013","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.pt.2021.11.004_bb0605","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/j.1462-5822.2011.01617.x","article-title":"Disruption of the Plasmodium falciparum liver-stage antigen-1 locus causes a differentiation defect in late liver-stage parasites","volume":"13","author":"Mikolajczak","year":"2011","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.pt.2021.11.004_bb0610","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ijpara.2013.01.010","article-title":"A new approach to generate a safe double-attenuated Plasmodium liver stage vaccine","volume":"43","author":"Nagel","year":"2013","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.pt.2021.11.004_bb0615","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00908-19","article-title":"Induction of effective immunity against Trypanosoma cruzi","volume":"88","author":"Williams","year":"2020","journal-title":"Infect. Immun."},{"key":"10.1016\/j.pt.2021.11.004_bb0620","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-3156.1997.tb00171.x","article-title":"Protective effect of Trypanosoma rangeli against infections with a highly virulent strain of Trypanosoma cruzi","volume":"2","author":"Zuniga","year":"1997","journal-title":"Tropical Med. Int. Health"},{"key":"10.1016\/j.pt.2021.11.004_bb0625","doi-asserted-by":"crossref","first-page":"6794","DOI":"10.4049\/jimmunol.161.12.6794","article-title":"Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response","volume":"161","author":"Alexander","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.pt.2021.11.004_bb0630","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1128\/IAI.70.1.62-68.2002","article-title":"Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination","volume":"70","author":"Papadopoulou","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/j.pt.2021.11.004_bb0635","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1128\/IAI.74.1.777-780.2006","article-title":"Immunization with persistent attenuated Delta lpg2 Leishmania major parasites requires adjuvant to provide protective immunity in C57BL\/6 mice","volume":"74","author":"Kebaier","year":"2006","journal-title":"Infect. Immun."},{"key":"10.1016\/j.pt.2021.11.004_bb0640","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ijpara.2005.03.008","article-title":"Characterisation of a Leishmania mexicana knockout lacking guanosine diphosphate-mannose pyrophosphorylase","volume":"35","author":"Stewart","year":"2005","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.pt.2021.11.004_bb0645","doi-asserted-by":"crossref","first-page":"10706","DOI":"10.1038\/srep10706","article-title":"Genetically engineered ascorbic acid-deficient live mutants of Leishmania donovani induce long lasting protective immunity against visceral leishmaniasis","volume":"5","author":"Anand","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pt.2021.11.004_bb0650","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.vaccine.2018.01.032","article-title":"Reduced pathogenicity of fructose-1,6-bisphosphatase deficient Leishmania donovani and its use as an attenuated strain to induce protective immunogenicity","volume":"36","author":"Saini","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.pt.2021.11.004_bb0655","doi-asserted-by":"crossref","first-page":"11627","DOI":"10.1038\/s41598-018-30076-7","article-title":"Growth arrested live-attenuated Leishmania infantum KHARON1 null mutants display cytokinesis defect and protective immunity in mice","volume":"8","author":"Santi","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pt.2021.11.004_bb0660","doi-asserted-by":"crossref","first-page":"18218","DOI":"10.1038\/s41598-020-75420-y","article-title":"DDX3 DEAD-box RNA helicase (Hel67) gene disruption impairs infectivity of Leishmania donovani and induces protective immunity against visceral leishmaniasis","volume":"10","author":"Pandey","year":"2020","journal-title":"Sci. Rep."}],"container-title":["Trends in Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492221002841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492221002841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:53:29Z","timestamp":1778615609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471492221002841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":132,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1471492221002841"],"URL":"https:\/\/doi.org\/10.1016\/j.pt.2021.11.004","relation":{},"ISSN":["1471-4922"],"issn-type":[{"value":"1471-4922","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Live attenuated vaccines, a favorable strategy to provide long-term immunity against protozoan diseases","name":"articletitle","label":"Article Title"},{"value":"Trends in Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pt.2021.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}